Q-omics provides the consensus-scored TDGF1P5 profile across patient tissues and cancer cell-line models. TDGF1P5 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, TDGF1P5 is differentially expressed in 13, with the highest sampling consensus in LUSC. Additionally, TDGF1P5 RNA expression shows 15,756 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LGG, LUSC, and UVM as cancer lineages where TDGF1P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TDGF1P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TDGF1P5 survival associations across molecular data types. TDGF1P5 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TDGF1P5 RNA expression–survival associations across cancer types. High TDGF1P5 expression shows unfavorable associations in LGG, UVM, READ, CESC and KIRC, but favorable associations in BRCA. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for TDGF1P5 RNA expression.
This table summarizes TDGF1P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TDGF1P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TDGF1P5 shows lower tumor expression in THCA and higher tumor expression in LUSC, STAD, COAD, KICH and BRCA. The LUSC box plot shows higher TDGF1P5 RNA expression in tumor versus normal tissue (log2 FC = +0.428, t-test p < 0.001).
This table shows molecular features associated with TDGF1P5 in patient tissues and cancer cell lines. In patient samples, TDGF1P5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
